{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:21:08Z","timestamp":1781533268802,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":3296,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.bbmt.2005.12.028","type":"journal-article","created":{"date-parts":[[2006,3,17]],"date-time":"2006-03-17T07:13:53Z","timestamp":1142579633000},"page":"472-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Pharmacokinetics of a Test Dose of Intravenous Busulfan Guide Dose Modifications to Achieve an Optimal Area Under the Curve of a Single Daily Dose of Intravenous Busulfan in Children Undergoing a Reduced-Intensity Conditioning Regimen with Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"12","author":[{"given":"Morris","family":"Kletzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jacobsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reggie","family":"Duerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2005.12.028_bib1","first-page":"225","article-title":"Association of busulfan area under the curve with veno-occlusive disease following BMT","volume":"17","author":"Dix","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib2","first-page":"9a","article-title":"Test dose and traditional first dose therapeutic drug monitoring for busulfan (Bu) fail to accurately predict steady-state systemic exposure in allogeneic bone marrow transplantation patients","volume":"20","author":"Lindley","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bbmt.2005.12.028_bib3","first-page":"145a","article-title":"Target dose adjustment of busulfan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or genetic disease [abstract 635]","volume":"94","author":"Bolinger","year":"1999","journal-title":"Blood"},{"issue":"suppl 4","key":"10.1016\/j.bbmt.2005.12.028_bib4","first-page":"18","article-title":"Busulfan disposition","volume":"20","author":"Grochow","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bbmt.2005.12.028_bib5","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood.V84.7.2144.2144","article-title":"Busulfan bioavailability","volume":"84","author":"Hassan","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2005.12.028_bib6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","article-title":"Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy","volume":"6","author":"Andersson","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib7","first-page":"11","article-title":"Acute graft vs host disease (GVHD) and toxicity correlate with busulfan systemic exposure (Bu-SE) after the IV BuCy2 regimen and stem cell transplantation (HSCT) for CML","volume":"96","author":"Andersson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2005.12.028_bib8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/bbmt.2002.v8.pm12374453","article-title":"Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation","volume":"8","author":"Fernandez","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib9","first-page":"92","article-title":"Validation of a limited sampling strategy (LSS) for pharmacokinetically directed dosing of high-dose intravenous busulfan (Busulfex) in BMT preparative regimens","volume":"7","author":"Vaughn","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","article-title":"Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation","volume":"8","author":"Andersson","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(04)16628-2","article-title":"Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children","volume":"364","author":"Jacobsohn","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2005.12.028_bib13","doi-asserted-by":"crossref","first-page":"326a","DOI":"10.1182\/blood.V104.11.1151.1151","article-title":"Single daily dose of IV busulfan in pediatrics, feasibility, pharmacokinetics (PK) and toxicity. 46th Annual American Society of Hematology Meeting","volume":"104","author":"Kletzel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2005.12.028_bib14","first-page":"31","article-title":"Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/clim.2001.5022","article-title":"Coexpression of normal and mutated CD40 ligand with deletion of a putative RNA lariat branchpoint sequence in X-linked hyper-IgM syndrome","volume":"99","author":"Zhu","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bbmt.2005.12.028_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2005.12.028_bib17","series-title":"Comparing Two Groups Unpaired t Test","first-page":"207","article-title":"Intuitive biostatistics","author":"Motulsky","year":"1995"},{"key":"10.1016\/j.bbmt.2005.12.028_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1399-3046.7.s3.2.x","article-title":"Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation","volume":"7","author":"Bostrom","year":"2003","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00007890-198506000-00004","article-title":"Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for non-malignant diseases","volume":"39","author":"Blazar","year":"1985","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2005.12.028_bib20","first-page":"52","article-title":"Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro","volume":"26","author":"Gibbs","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bbmt.2005.12.028_bib21","first-page":"843","article-title":"Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders","volume":"18","author":"Hassan","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF00688324","article-title":"Busulphan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation","volume":"37","author":"Vassal","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2005.12.028_bib23","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood.V84.7.2357.2357","article-title":"Busulphan pharmacokinetics using a single daily high dose regimen in children with acute leukemia","volume":"84","author":"Shaw","year":"1994","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.bbmt.2005.12.028_bib24","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1038\/sj.bmt.1702351","article-title":"Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)","volume":"25","author":"Andersson","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib25","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/sj.leu.2401921","article-title":"A phase I\/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation","volume":"14","author":"Olavarria","year":"2000","journal-title":"Leukemia"},{"issue":"suppl","key":"10.1016\/j.bbmt.2005.12.028_bib26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbmt.2003.12.111","article-title":"A test dose of I.V. busulfan is predictive of area under the curve (AUC) of a single daily dose of I.V. Bu in pediatric patients undergoing a reduced intensity (RI) hematopoietic stem cell transplant (HSCT)","volume":"10","author":"Kletzel","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib27","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1365-2125.2002.01555.x","article-title":"Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation","volume":"53","author":"Cremers","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2005.12.028_bib28","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood.V75.8.1723.1723","article-title":"Busulfan disposition in children","volume":"75","author":"Grochow","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2005.12.028_bib29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF00689702","article-title":"Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology","volume":"28","author":"Hassan","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2005.12.028_bib30","first-page":"843","article-title":"Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders","volume":"18","author":"Hassan","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib31","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/sj.bmt.1703739","article-title":"A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation","volume":"30","author":"Hassan","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib32","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/sj.bmt.1704209","article-title":"Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants","volume":"32","author":"Dalle","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.bmt.1704707","article-title":"Intravenous busulfan in children prior to stem cell transplantation","volume":"35","author":"Zwaveling","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.leu.2403591","article-title":"Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies","volume":"19","author":"Shimoni","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2005.12.028_bib35","doi-asserted-by":"crossref","first-page":"636a","DOI":"10.1182\/blood.V104.11.2314.2314","article-title":"Efficacy of reduced intensity conditioning (RIC) with Flu-Bu-ATG and allogeneic hematopoietic stem cell transplantation for pediatric ALL","volume":"104","author":"Duerst","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2005.12.028_bib36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/sj.bmt.1704560","article-title":"Busulphan given as four single daily doses of 150 mg\/m2 is safe and effective in children of all ages","volume":"34","author":"Shaw","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2005.12.028_bib37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.bmt.1704446","article-title":"busulfan in pediatrics","volume":"33","author":"Nguyen","year":"2004","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879105014114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879105014114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:26:31Z","timestamp":1761056791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879105014114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S1083879105014114"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2005.12.028","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of a Test Dose of Intravenous Busulfan Guide Dose Modifications to Achieve an Optimal Area Under the Curve of a Single Daily Dose of Intravenous Busulfan in Children Undergoing a Reduced-Intensity Conditioning Regimen with Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2005.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}